Comparison tool

Retatrutide vs Cagrilintide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

RetatrutideCagrilintide

Share this peptide comparison

Property	Retatrutide	Cagrilintide
Category	Weight Loss	Weight Loss
Also known as	LY3437943, Triple G	AM833, NN9838, CagriSema (combination)
FDA approved	No	No
Clinical status	Source-reported Phase 3 TRIUMPH-1 pivotal trial update (May 2026): 28.3 % mean weight loss at 80 week with 12 mg, and 45 % of patients lost 30 % or more. It calls this the largest Phase 3 obesity-drug loss result and expects an NDA submission late 2026–Q1 2027. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Weight loss, metabolic syndrome, liver fat reduction	Weight loss, appetite control, combination therapy
How it works	Retatrutide is described as an agonist at GIP, GLP-1, and glucagon receptors. The source links GLP-1 signaling to lower appetite and delayed stomach emptying, GIP to insulin response and nutrient handling by fat tissue, and glucagon receptor activity to hepatic energy expenditure and fat burning. It emphasizes that the individual contribution of each receptor in humans is still uncertain.	Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.
Typical dosing	4-12 mg weekly · Once weekly, same day each week	2.4 mg weekly · Once weekly
Research dosing	0.5mg weekly (starting) · Long-term use expected · Subcutaneous injection weekly	2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly
Typical duration	Long-term use expected	Long-term / chronic use expected
Administration	Subcutaneous injection weekly	Subcutaneous injection once weekly
Timing	Morning, same day each week With or without food	Any consistent time weekly With or without food
Evidence level	Clinical Trials	Clinical Trials
Possible side effects	Nausea (dose-related) (Reported as dose-related.) Diarrhea (The source says individual responses can vary with dose, duration, and personal health factors.) Vomiting +6 more Constipation Heart rate increases Hypersensitivity reactions Dysesthesia - skin sensitivity/tingling (~21% at highest dose, TRIUMPH-4 data) (The reported rate refers to the highest dose in TRIUMPH-4 data.) Pancreatitis (rare) (Listed by the source as rare.) Currently in Phase 3 trials (This is a trial-status statement included in the source side-effect list, not an adverse effect.)	Nausea (Reported as common and usually temporary in the source.) Vomiting (Listed among reported gastrointestinal effects.) Diarrhea (Listed among reported gastrointestinal effects.) +8 more Constipation (Listed among reported gastrointestinal effects.) Abdominal pain (Reported in the source as a gastrointestinal adverse effect.) Injection site reactions (Reported in the source without additional severity detail.) Decreased appetite (Reported in the source; clinical relevance depends on study context.) Headache (Reported in the source without additional severity detail.) Dyspepsia (Reported in the source as a gastrointestinal symptom.) Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.) Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)
Research summary	According to the source summary, Jastreboff and colleagues reported a 2023 NEJM Phase 2 randomized trial involving 338 adults with obesity but no type 2 diabetes. The 48 week trial reported a mean reduction close to 24 percent at 12 mg, with no clear plateau by that endpoint. It also reports that a large majority of participants with baseline prediabetes had normal blood sugar at follow-up. Nausea, vomiting, and diarrhea predominated and were described as dose-dependent. The summary says larger, longer Phase 3 work was intended to examine durability and safety.	The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.
References	Source Source +1 more Source	Source Source +3 more Source Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Retatrutide

Cagrilintide

Category

Weight Loss

Also known as

LY3437943, Triple G

AM833, NN9838, CagriSema (combination)

FDA approved

Clinical status

Source-reported Phase 3 TRIUMPH-1 pivotal trial update (May 2026): 28.3 % mean weight loss at 80 week with 12 mg, and 45 % of patients lost 30 % or more. It calls this the largest Phase 3 obesity-drug loss result and expects an NDA submission late 2026–Q1 2027.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Weight loss, metabolic syndrome, liver fat reduction

Weight loss, appetite control, combination therapy

How it works

Retatrutide is described as an agonist at GIP, GLP-1, and glucagon receptors. The source links GLP-1 signaling to lower appetite and delayed stomach emptying, GIP to insulin response and nutrient handling by fat tissue, and glucagon receptor activity to hepatic energy expenditure and fat burning. It emphasizes that the individual contribution of each receptor in humans is still uncertain.

Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.

Typical dosing

4-12 mg weekly · Once weekly, same day each week

2.4 mg weekly · Once weekly

Research dosing

0.5mg weekly (starting) · Long-term use expected · Subcutaneous injection weekly

2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly

Typical duration

Long-term use expected

Long-term / chronic use expected

Administration

Subcutaneous injection weekly

Subcutaneous injection once weekly

Timing

Morning, same day each week

With or without food

Any consistent time weekly

With or without food

Evidence level

Clinical Trials

Possible side effects

Nausea (dose-related) (Reported as dose-related.)
Diarrhea (The source says individual responses can vary with dose, duration, and personal health factors.)
Vomiting

+6 more

Constipation
Heart rate increases
Hypersensitivity reactions
Dysesthesia - skin sensitivity/tingling (~21% at highest dose, TRIUMPH-4 data) (The reported rate refers to the highest dose in TRIUMPH-4 data.)
Pancreatitis (rare) (Listed by the source as rare.)
Currently in Phase 3 trials (This is a trial-status statement included in the source side-effect list, not an adverse effect.)

Nausea (Reported as common and usually temporary in the source.)
Vomiting (Listed among reported gastrointestinal effects.)
Diarrhea (Listed among reported gastrointestinal effects.)

+8 more

Constipation (Listed among reported gastrointestinal effects.)
Abdominal pain (Reported in the source as a gastrointestinal adverse effect.)
Injection site reactions (Reported in the source without additional severity detail.)
Decreased appetite (Reported in the source; clinical relevance depends on study context.)
Headache (Reported in the source without additional severity detail.)
Dyspepsia (Reported in the source as a gastrointestinal symptom.)
Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.)
Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)

Research summary

According to the source summary, Jastreboff and colleagues reported a 2023 NEJM Phase 2 randomized trial involving 338 adults with obesity but no type 2 diabetes. The 48 week trial reported a mean reduction close to 24 percent at 12 mg, with no clear plateau by that endpoint. It also reports that a large majority of participants with baseline prediabetes had normal blood sugar at follow-up. Nausea, vomiting, and diarrhea predominated and were described as dose-dependent. The summary says larger, longer Phase 3 work was intended to examine durability and safety.

The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.

References

+1 more

+3 more

Full profile